BioCentury | Oct 31, 2020
Distillery Therapeutics

TREML4 as a sepsis target

...with Pseudomonas aeruginosa after recovery from polymicrobial sepsis, systemic TREML4 knockout reduced lung epithelial damage and P. aeruginosa-induced...
BioCentury | Apr 23, 2020
Finance

Crossovers back Affinivax in $120M series B to broaden clinical vaccine pipeline

Though it once felt it could do without a large cash infusion from VCs, Affinivax has chosen to raise $120 million in a series B round that is designed to advance a handful of preclinical...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

FDA approves Pear’s cognitive behavioral insomnia therapy FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia. The prescription digital therapeutic is the first to be approved via simultaneous review under the standard 510(k)...
BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...
BioCentury | Feb 28, 2020
Distillery Therapeutics

Sodium nitrite plus EDTA for bacterial infections

...EDTA), could treat infections by Pseudomonas aeruginosa and other bacteria. The two compounds synergistically inhibited P. aeruginosa...
...coli , Klebsiella pneumoniae , Proteus mirabilis and Salmonella typhimurium . In mice with chronic P. aeruginosa...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Hydrogel-delivered, thrombin-derived peptide to treat and prevent Staphylococcus and Pseudomonas infections

...A polymer-based hydrogel containing the thrombin-derived peptide TCP-25 could treat and prevent S. aureus and P. aeruginosa...
...to and neutralize bacterial LPS, showed a more than three-log reduction of S. aureus and P. aeruginosa...
...bacterial load in mice when given both before and after inoculation with S. aureus or P. aeruginosa...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

In response to an expanding funding gap for antimicrobial resistance companies, Novo Holdings is expanding the remit of its early stage REPAIR Impact Fund to include investments as late as Phase II for the fund’s...
BioCentury | Jan 18, 2020
Finance

Novo seeks to REPAIR funding in antibiotics companies

In response to an expanding funding gap for antimicrobial resistance companies, Novo Holdings is expanding the remit of its early stage REPAIR Impact Fund to include investments as late as Phase II for the fund’s...
BioCentury | Dec 19, 2019
Preclinical News

Dec. 19 Preclinical Quick Takes: First recipients of AACR-MPM Capital impact fund grants revealed; plus pre-conception protection with NIH’s Zika vaccine, Vivet

...survival and reduced bacterial burden in the lungs, kidney and spleen in rabbit models of P. aeruginosa...
BioCentury | Oct 17, 2019

CPS-based bioconjugate vaccine for hypervirulent Klebsiella

DISEASE CATEGORY: Infectious disease INDICATION: Gram-negative bacterial infection A K. pneumoniae CPS-based glycoconjugate vaccine could protect mice against lethal infection by K. pneumoniae . The vaccine against K. pneumoniae serotypes K1 and K2, which cause most...
Items per page:
1 - 10 of 698